Clinical Trials

Inclusion Criteria:

1. Age ≥ 50 years and ≤ 89 years

2. An ETDRS BCVA letter score between ≤ 78 and ≥ 40 in the study eye

3. Diagnosis of subfoveal CNV secondary to AMD in the study eye previously treated with
anti-VEGF

4. Must be pseudophakic (at least 12 weeks postcataract surgery) in the study eye.

5. Willing and able to provide written, signed informed consent for this study

6. Participants must have demonstrated a meaningful response to anti-VEGF therapy at
study entry

Exclusion Criteria:

1. CNV or macular edema in the study eye secondary to any causes other than AMD

2. Subfoveal fibrosis or atrophy in the study eye

3. Any condition in the investigator's opinion that could limit VA improvement in the
study eye

4. Active or history of retinal detachment in the study eye

5. Uncontrolled glaucoma in the study eye

6. History of intraocular surgery in the study eye within 12 weeks prior to Screening
Visit 1

7. History of intravitreal therapy in the study eye, such as intravitreal steroid
injection or investigational product, other than anti-VEGF therapy, in the 6 months
prior to Screening Visit 1.

8. Prior treatment with gene therapy.

9. Recent myocardial infarction, cerebrovascular accident, or transient ischemic attack
within the past 6 months.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 7/7/23. Questions regarding updates should be directed to the study team contact.